Financial Review: VIVUS (VVUS) vs. The Competition
VIVUS (NASDAQ: VVUS) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare VIVUS to similar companies based on the strength of its analyst recommendations, risk, institutional ownership, dividends, valuation, earnings and profitability.
Insider & Institutional Ownership
35.7% of VIVUS shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 4.4% of VIVUS shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for VIVUS and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 6.22%. Given VIVUS’s rivals higher probable upside, analysts plainly believe VIVUS has less favorable growth aspects than its rivals.
Risk & Volatility
VIVUS has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, VIVUS’s rivals have a beta of 1.28, meaning that their average stock price is 28% more volatile than the S&P 500.
Valuation & Earnings
This table compares VIVUS and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|VIVUS||$133.40 million||$67.14 million||2.66|
|VIVUS Competitors||$579.30 million||$241.72 million||-6.66|
VIVUS’s rivals have higher revenue and earnings than VIVUS. VIVUS is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares VIVUS and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
VIVUS rivals beat VIVUS on 6 of the 10 factors compared.
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.